Pharma company will produce seven vaccines, as nation aims to strengthen status as a life sciences hub.
Sanofi, alongside Lifera, a biopharma company in Saudi Arabia, and Arabio, a pharma manufacturer, have signed a memorandum of understanding (MoU), which aims to strengthen local manufacturing of vaccines in the nation.
Per the terms of the MOU, Sanofi, Lifera, and Arabio will explore opportunities for collaboration to help advance Saudi Arabia's vaccines localization strategy through a range of proposed initiatives that include Lifera being a contract manufacturer to Sanofi, through state-of-the-art manufacturing facilities and capabilities, as well as leveraging Arabio and its major owner Tamer Group's local and regional distribution strength in vaccines and other key pharma products. Sanofi will initially manufacture seven vaccines which are part of the mandatory immunization schedule to help increase their accessibility to the local community and to potentially target the regional export market.
“ … Since the inception of Arabio, our aspiration has been to contribute to Saudi Arabia's efforts to prevent diseases and ensure biosecurity. Arabio and the Tamer Group are focused on supplying consumers in Saudi Arabia with healthcare products of the highest quality together with a broad network of leading global partner companies,” says Faisal Tamer, chairman of Arabio and vice-chairman of Tamer Group. “We believe this potential partnership is just the beginning of the development of the Saudi biopharmaceutical sector and will create several new opportunities for talent to grow in this vital sector."